What compounds target RET?

BiohacksAI has identified 106 compounds that interact with RET (ret proto-oncogene). Top compounds include: gefitinib, erlotinib, ibrutinib, tofacitinib, cabozantinib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is RET (ret proto-oncogene)?

RET is ret proto-oncogene. It is a molecular target for 106 compounds documented in PubMed bioassay data. UniProt ID: P07949. NCBI Gene ID: 5979.

RET

MOLECULAR TARGET

ret proto-oncogene

UniProt: P07949 NCBI Gene: 5979106 compounds

RET (ret proto-oncogene) is targeted by 106 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting RET

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	gefitinib	5.67	290
2	erlotinib	5.55	256
3	ibrutinib	4.86	128
4	tofacitinib	4.65	104
5	cabozantinib	4.39	80
6	foretinib	4.34	76
7	tozasertib	4.33	75
8	vandetanib	4.30	73
9	ponatinib	4.26	70
10	ruxolitinib	4.23	68
11	ceritinib	4.19	65
12	nilotinib	4.17	64
13	bosutinib	4.08	58
14	doramapimod	4.06	57
15	quizartinib	3.99	53
16	semaxanib	3.93	50
17	midostaurin	3.85	46
18	brigatinib	3.81	44
19	Sorafenib	3.76	42
20	pazopanib	3.69	39
21	vatalanib	3.69	39
22	nintedanib	3.61	36
23	regorafenib	3.56	34
24	baricitinib	3.56	34
25	canertinib	3.53	33
26	tae 684	3.43	30
27	fedratinib	3.40	29
28	gilteritinib	3.40	29
29	bms 777607	3.37	28
30	linifanib	3.33	27
31	saracatinib	3.33	27
32	sgi 1776	3.26	25
33	entrectinib	3.18	23
34	alectinib	3.18	23
35	dovitinib	3.09	21
36	jnj 7706621	3.09	21
37	at 9283	3.09	21
38	dasatinib anhydrous	3.09	21
39	upadacitinib	3.09	21
40	lestaurtinib	3.04	20
41	lenvatinib	3.04	20
42	pf 03758309	3.00	19
43	danusertib	2.94	18
44	defosbarasertib	2.89	17
45	orantinib	2.89	17
46	barasertib	2.89	17
47	cyclobenzaprine	2.89	17
48	r 406	2.83	16
49	k 252a	2.83	16
50	cediranib	2.83	16

Showing top 50 of 106 compounds. Use the BiohacksAI search to explore all RET modulators.

About RET as a Drug Target

RET (ret proto-oncogene) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 106 compounds with documented RET interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

RET inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.